Renal thrombotic microangiopathy impairs renal function recovery in lupus nephritis Authors: Manhuai Zhang, Xinxin Zhang, Wang Xiang, Jianwen Yu, Xin Wang, Hongjian Ye, Zhong Zhong, Ruihan Tang, Xi Xia, Wei Chen Published: 2025 ABSTRACT ABSTRACTBackgroundRenal thrombotic microangiopathy (TMA) remains a challenge for lupus nephritis (LN) patients. The purpose of this study was to determine the prognostic significance of renal TMA in patients with LN.MethodsPatients were recruited from the LN database (http://ln.medidata.cn) of the First Affiliated Hospital of Sun Yat-Sen University between 2001 and 2023. To assess the association between renal TMA and kidney recovery outcomes, propensity score matching (PSM), and Cox proportional hazards regression analysis were used.Results5.17% LN patients had kidney biopsies showing TMA. After PSM, patients with renal TMA exhibited lower scores on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Activity Index (AI) scores in renal biopsies. Renal TMA was independently associated with deteriorated renal function recovery compared with non-renal TMA [hazard ratio (HR) 0.62; 95% confidence interval (CI) 0.42–0.94, P = .022). This association remained significant after PSM (HR: 0.50; 95% CI: 0.31–0.82, P = .004). Additionally, renal TMA was independently associated with higher risk of renal replacement therapy (RRT) (HR: 6.90; 95% CI: 3.57–13.30, P < .001) in LN patients. The proportion of glomerulosclerosis is a predictive factor for renal function recovery in LN patients with renal TMA (HR: 0.62; 95% CI: 0.40–0.95, P = .027).ConclusionsRenal TMA is strongly associated with poorer renal function recovery in LN patients. Furthermore, a higher degree of glomerulosclerosis is a significant risk factor for impaired recovery in these patients. What was known: Renal thrombotic microangiopathy (TMA) has been associated with more severe clinical and histological activity, as well as significantly inferior long-term renal outcomes in lupus nephritis (LN). Renal thrombotic microangiopathy (TMA) has been associated with more severe clinical and histological activity, as well as significantly inferior long-term renal outcomes in lupus nephritis (LN). This study adds: Renal TMA is strongly associated with poorer renal function recovery in patients with LN, even among those who exhibit lower scores on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Activity Index (AI). Renal TMA is strongly associated with poorer renal function recovery in patients with LN, even among those who exhibit lower scores on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Activity Index (AI). Our study provides evidence that a higher degree of glomerulosclerosis is a significant risk factor for impaired recovery in these patients. Our study provides evidence that a higher degree of glomerulosclerosis is a significant risk factor for impaired recovery in these patients. Potential impact: The degree of glomerulosclerosis in renal biopsy can help doctors assess the likelihood of renal function recovery in LN patients with renal TMA, thereby optimizing individualized treatment decisions. The degree of glomerulosclerosis in renal biopsy can help doctors assess the likelihood of renal function recovery in LN patients with renal TMA, thereby optimizing individualized treatment decisions. INTRODUCTION Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies and the deposition of immune complexes [1, 2]. Among its complications, lupus nephritis (LN) occurs in 20% to 60% of SLE patients leading to mortality, especially in those who develop kidney failure [3]. Renal thrombotic microangiopathy (TMA), a pathological diagnosis, is characterized by the formation of microthrombi in the glomerular capillaries or the presence of endothelial cell swelling and onion-skin-like changes in small arteries [4]. In previous research, the incidence of renal TMA in LN has been reported to vary widely, ranging from 0.5% to 24.3% [5–7]. This substantial discrepancy is likely attributable to the fact that diagnosing renal TMA in the context of LN can be quite challenging. Renal TMA was associated with more severe clinical and histological activity, and significantly inferior long-term renal outcome in LN [8, 9]. Nevertheless, studies indicated that LN patients with renal TMA had comparable outcomes to those without if estimated glomerular filtration rate (eGFR) and biopsy characteristics were similar and their response to therapy and end-stage kidney disease (ESKD) risk were not significantly different [10, 11]. Current studies of renal TMA in LN are limited by the small sample sizes and short-term follow up. To address this gap, we conducted a study to investigate the clinicopathological features of LN patients with renal TMA. Furthermore, we investigated the associated predictors of renal outcomes in this cohort of patients. MATERIALS AND METHODS Study population The present single-center analysis included data extracted from the High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort, NCT06682507). A total of 1520 kidney biopsies proved LN patients were included in the period from January 2001 to December 2023. Patients were retrospectively enrolled from January 2001 to December 2016 and patients were prospectively enrolled beginning in January 2017. All enrolled patients fulfilled the 1997 revised American College of Rheumatology criteria for SLE [12, 13]. We excluded 173 individuals with missing variables on medical record and 129 individuals with nine or fewer glomeruli. Thus a total of 1218 patients were enrolled. Renal TMA was defined according to renal biopsy [14]. A 1:2 propensity score matching (PSM) approach was used to match each of the 63 LN-TMA patients with two individuals from the LN Non-TMA cohort, based on their age, gender, proteinuria, serum creatinine values, and LN classification—all of which are closely related to the outcomes (Fig. 1). Flowchart of patient selection. Clinical definitions We collected information at the time of admission for renal biopsy on demographic information, clinical parameter information and laboratory tests for all participants. The clinical characteristics, including lupus symptoms, were collected based on the medical records. The clinical disease activity was assessed via the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [15]. The eGFR was obtained using the CKD-EPI two-level race equation [16]. Prescription data included steroids, immunosuppressant, hydroxychloroquine, and anticoagulants. Pathologic diagnostic criteria Kidney biopsies were examined by light microscopy, direct immunofluorescence, and electron microscopy, with all specimens independently reviewed by two pathologists. Renal TMA was defined as endothelial cell swelling, luminal narrowing or obliteration, and thrombus formation in interlobular arteries, arterioles, and glomerular capillaries on light microscopy with H&E, silver, and Masson’s trichrome staining. Electron microscopy further confirmed glomerular endothelial cell swelling, detachment from the basement membrane, and widening of the subendothelial space [8]. Pathological parameters, including the activity index (AI) and chronicity index (CI), were assessed in accordance with the criteria of the ISN/RPS 2018 [17]. Outcomes The primary outcome of this study was recovery of kidney function, which was defined as a decrease of serum creatinine level from baseline by >50%, a decrease in serum creatinine level to reference range levels [based on the reference range of <1.3 mg/dl (to convert to micromoles per liter, multiply by 88.4), as established by the hospital], or kidney survival free from hemodialysis or peritoneal dialysis for at least 1 month for dialysis-dependent patients [18]. The secondary outcome was renal replacement therapy (RRT), which was defined as the need for chronic dialysis or kidney transplantation. Patients were monitored by nephrologists and trained nurses through outpatient visits or telephone interviews. During the first year following biopsy, kidney function was assessed monthly, and thereafter, evaluations were conducted every three months. The end time of follow-up period was 31 December 2024. Statistical analyses Continuous variables were reported as mean and standard deviation, and categorical variables as frequencies and percentages. We utilized weighted Student’s t-test for normally distributed continuous variables, Mann–Whitney U-test for non-normally distributed continuous variables, and chi-square test for categorical variables to compare baseline characteristics. Kidney and patient survival was estimated using the Kaplan–Meier method. We examined the significant association between survival and clinical factors using univariate and multivariate Cox proportional hazards models. All tests were two-tailed and P < .05 was considered statistically significant. Data processing and analysis were performed using R v.4.3.3 (2024–02-29), along with Zstats v.1.0 (www.zstats.net). RESULTS Baseline demographics and characteristics The proportion of renal TMA was 5.17% (63/1218). We found that patients with renal TMA were younger and more likely to suffer from hypertension and anemia. Renal TMA patients had higher serum creatinine and lower platelet and dsDNA counts. Moreover, the AI and CI scores was higher in the TMA group than in the non-TMA group. After PSM, patients with TMA exhibited lower platelet and lower scores on the SLEDAI and the AI scores in renal biopsies (Table 1). The baseline characteristics indicated that a well-balanced distribution was achieved between the two groups (SMD < 0.1, Supplementary Fig. S1). Table 1:Baseline characteristics of LN patients according to renal vascular lesions TMA.VariableTMANon-TMAMatchedNon-TMA P value P valueaNumber of patients631155126Age, median [IQR]37.00 [28.00, 46.50]41.00 [33.00, 52.50]35.50 [28.00, 47.00].008.722Sex, n (%).991.741 Female50 (79.37)927 (80.26) 104 (82.53) Male13 (20.63)228 (19.74) 22 (17.47)Hypertension, n (%)11 (17.46)77 (6.67)18 ( 14.28).003.721Anemia, n (%)61 (96.82)810 (70.12)109 ( 86.5)<.001.049SLEDAI, median [IQR]13.00 [11.00, 17.00]15.00 [11.00, 19.00]16.00 [14.00, 21.00].301.024 Laboratory marker Creatinine, μmol/l, median [IQR]272.00 [164.00, 418.50]86.00 [61.00, 156.00]217.50 [89.25, 501.00]<.001.431eGFR, ml/min/1.732, median [IQR]20.79 [11.06, 38.64]74.44 [36.71, 106.62]24.44 [9.33, 71.69]<.001.628eGFR stage, n (%)<.001.013 90 ml/min/1.7328 (12.7)469 (40.6)20 (15.9) 60–89 ml/min/1.7324 (6.3)227 (19.7)18 (14.3) 30–59 ml/min/1.7328 (12.7)236 (20.4)18 (14.3) 15–29 ml/min/1.73224 (38.1)116 (10.0)20 (15.9) <15 ml/min/1.73219 (30.2)107 (9.3)50 (39.7)Proteinuria, g/24 hours, median [IQR]2.66 [1.22, 5.57]2.22 [1.00, 4.36]2.74 [1.38, 4.85].264.897Platelet, 10⁹/l, median [IQR]159.00 [118.00, 216.25]200.00 [148.00, 260.00]199.00 [148.00, 286.00]<.001.001LDH, U/l, median [IQR]318.00 [269.00, 384.00]260.50 [219.00, 363.75]270.50 [229.75, 323.75].055.255broken RBC, n (%)12 (57.10)10 (35.70)2 ( 66.7).2291.000ANA, n (%)56 (94.91)1092 (96.46)118 (94.4).7911.000dsDNA, n (%)39 (66.10)902 (80.00)106 (84.80).016.007C3, g/l, median [IQR]0.46 [0.35, 0.62]0.44 [0.29, 0.64]0.39 [0.28, 0.60].542.184C4, g/l, median [IQR]0.12 [0.07, 0.16]0.10 [0.06, 0.16]0.10 [0.06, 0.16].318.744 Treatment before biopsy Steroid, n (%)63 (100.00)1044 (98.10)126 (100.00).722Immunosuppressant, n (%)34 (59.60)559 (54.50)52 (50.50).531.343Hydroxychloroquine, n (%)18 (31.60)120 (12.0)16 (15.70)<.001.032Anticoagulants, n (%)10 (17.50)290 (29.30)29 (24.60).078.160Plasma exchange, n (%)6 (9.5)2 (0.2)0 (0.0)<.001.002 Treatment after biopsy Anticoagulants, n (%)14 (24.6)292 (29.6)29 (24.60).5091.000Plasma exchange, n (%)9 (14.3)0 (0.0)0 (0.0)<.001<.001Rituximab/belimumab, n (%)6 (9.5)10 (0.9)0 (0.0)<.001<.001 Pathology Characteristic Pathology classification, n (%).010.797 I0 (0.00)12 (1.00)0 (0.00) II1 (1.60)78 (6.80)4 (3.20) III5 (7.90)83 (7.20)9 (7.10) IV44 (69.80)607 (52.60)86 (68.30) V1 (1.60)178 (15.40)3 (2.40) V + III1 (1.60)66 (5.70)0 (0.0-) V + IV9 (14.30)114 (9.90)17 (13.50) VI2 (3.20)17 (1.50)7 (5.60)AI score, median [IQR]9.00 [6.00, 11.00]5.00 [3.00, 7.00]7.00 [5.00, 10.00]<.001.007 Endocapillary hypercellularity2.00 [1.00, 3.00]2.00 [1.00, 3.00]2.00 [2.00, 3.00].64.074 Neutrophils and/or karyorrhexis2.00 [1.00, 2.00]1.00 [0.00, 2.00]1.00 [0.00, 2.00]<.001.022 Fibrinoid necrosis0.00 [0.00, 1.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]<.001<.001 Hyaline deposits (wire loop and/or hyaline thrombi)0.00 [0.00, 1.00]0.00 [0.00, 1.00]0.00 [0.00, 1.00].004.288 Cellular/fibrocellular crescents2.00 [2.00, 4.00]0.00 [0.00, 2.00]0.00 [0.00, 4.00]<.001.002 Interstitial inflammation1.00 [1.00, 2.00]1.00 [0.00, 1.00]1.00 [1.00, 2.00]<.001.679CI score, median [IQR]4.00 [2.00, 6.00]3.00 [2.00, 4.00]4.00 [2.00, 7.00].007.571 Total glomerulosclerosis (global + segmental)1.00 [0.00, 2.00]0.00 [0.00, 1.00]0.00 [0.00, 2.00]<.001.285 Fibrous crescents0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 1.00].14.327 Interstitial fibrosis1.00 [1.00, 2.00]1.00 [0.00, 1.00]1.00 [0.00, 2.00]<.001.232 Tubular atrophy1.00 [1.00, 2.00]0.00 [0.00, 1.00]1.00 [0.00, 2.00]<.001.006LDH, lactate dehydrogenase; RBC, red blood cell. aP-value: TMA versus Non-TMA; P-valuea: TMA versus matched Matched Non-TMA. Baseline characteristics of LN patients according to renal vascular lesions TMA. LDH, lactate dehydrogenase; RBC, red blood cell. aP-value: TMA versus Non-TMA; P-valuea: TMA versus matched Matched Non-TMA. Representative light and electron microscopic findings of renal TMA are presented in Supplementary Fig. S2. Light microscopy revealed typical pathological changes in TMA, including significant intimal thickening of the renal artery (Supplementary Fig. S2a) and a ‘double-track’ appearance of the glomerular basement membrane (Supplementary Fig. S2b). Electron microscopy showed endothelial cell swelling, leading to narrowing of the capillary lumen (Supplementary Fig. S2c). Risk of renal TMA on outcomes The cumulative incidence of renal function recovery was significantly lower in patients with TMA compared to those without TMA (overall comparison, P = .022; PSM comparison, P = .004, Fig. 2). This difference remained statistically significant after adjustment for the overall comparison (HR: 0.53, 95% CI: 0.34–0.87, P = .011) and the PSM comparison (HR: 0.50; 95% CI: 0.31–0.82, P = .004) (Table 2). Subgroup analyses (Supplementary Fig. S3) showed no significant interactions between renal TMA and other main covariates on the primary outcome of renal function recovery (all P for interaction >.05). Cumulative risk of kidney function recovery in LN patients with or without TMA. Cumulative risk of primary outcome of kidney function recovery in LN patients with or without TMA in the overall comparison (a) and the propensity score-matched comparison (b). Table 2:Association between TMA and study outcome within the crude analysis, multivariable analysis, and propensity score analysis.VariableHR (95% CI) P valueThe primary outcome of recovery of renal function TMA Crude analysisa0.62 (0.42–0.94).022 Multivariable analysisb0.53 (0.34–0.87).011 PSMc0.50 (0.31–0.82).004The second outcome of RRT TMA Crude analysisa6.90 (3.57–13.30)<.001 Multivariable analysisb6.37 (3.28–12.40)<.001 PSMc11.20 (2.50–50.00).002aThe HRs from the bivariable model in all patients from the unmatched study.bThe HRs from the multivariable stratified Cox proportional hazards regression model, with additional covariate adjustment.cThe HR from propensity score-matched sample, constructed using 1:2 nearest neighbor matching with a 0.02 caliper. Association between TMA and study outcome within the crude analysis, multivariable analysis, and propensity score analysis. The HRs from the bivariable model in all patients from the unmatched study. The HRs from the multivariable stratified Cox proportional hazards regression model, with additional covariate adjustment. The HR from propensity score-matched sample, constructed using 1:2 nearest neighbor matching with a 0.02 caliper. Patients with TMA showed worse outcomes of RRT than those with non-TMA (overall comparison, P < .001; Table 2). This difference remained statistically significant after adjustment for the overall comparison (HR: 6.37, 95% CI: 3.28–12.40, P < .001) and the PSM comparison (HR: 11.20; 95% CI: 2.50–50.00, P = .002) (Table 2). For comparability, we also evaluated standard endpoints. During follow up, 36.5% (23/63) of patients with TMA achieved renal function recovery. Notably, the rates of complete or partial remission were comparable between the TMA and non-TMA groups (28.6% vs. 23.7%, P = .595). However, the incidences of ESKD (12.7% vs. 2.7%, P = .012) and death (4.8% vs. 2.5%, P = .660) were higher in the TMA group. Predictors of renal function recovery in LN patients After the multivariable Cox regression analysis, patients with TMA (adjusted HR: 0.53, 95% CI: 0.34–0.87, P = .011) and a higher level of total glomerulosclerosis (adjusted HR: 0.79, 95% CI: 0.63–0.98, P = .031) were identified as risk factors for renal function recovery in LN patients (Table 3). Table 3:Univariate and multivariable Cox regression analysis for the primary outcome of renal function recovery in the PSM cohort.VariableUnivariable HR (95% CI) P valueMultivariable HR (95% CI) P valueTMA0.50 (0.31–0.82).0040.53 (0.34–0.87).011Age0.98 (0.96–1.00).027Sex1.20 (0.68–2.12).520Hypertension1.22 (0.62–2.40).557Anemia0.86 (0.39–1.87).700Creatinine, μmol/l1.00 (0.99–1.00).010eGFR, ml/min/1.7321.01 (1.00–1.01).0121.00 (0.99–1.01).169Proteinuria, g/24 hours1.01 (0.95–1.07).733LDH, U/l1.00 (0.99–1.00).344Broken RBC0.41 (0.04–4.52).465ANA1.24 (0.45–3.41).672dsDNA1.74 (0.98–3.11).061C3, g/l0.98 (0.32–2.94).964C4, g/l0.64 (0.06–7.02).711AI score0.96 (0.91–1.02).222Endocapillary hypercellularity1.11 (0.88–1.42).376Neutrophils and/or karyorrhexis0.93 (0.76–1.14).465Fibrinoid necrosis0.77 (0.57–1.04).091Hyaline deposits (wire loop and/or hyaline thrombi)1.11 (0.82–1.51).499Cellular/fibrocellular crescents0.92 (0.83–1.02).122Interstitial inflammation0.96 (0.76–1.21).696CI score0.92 (0.84–1.01).073Total glomerulosclerosis (global + segmental)0.74 (0.61–0.91).0040.79 (0.63–0.98).031Fibrous crescents0.98 (0.76–1.26).865Interstitial fibrosis0.92 (0.75–1.13).425Tubular atrophy0.92 (0.74–1.14).439 Univariate and multivariable Cox regression analysis for the primary outcome of renal function recovery in the PSM cohort. In LN patients with TMA, a higher degree of total glomerulosclerosis was identified as a significant risk factor for poorer renal function recovery (adjusted HR: 0.62, 95% CI: 0.40–0.95, P = .027, Table 4). Table 4:Univariate and multivariable Cox regression analysis for the primary outcome of renal function recovery in the TMA cohort.VariableUnivariable HR (95% CI) P valueMultivariable HR (95% CI) P valueAge0.99 (0.95–1.03).532Sex1.65 (0.63–4.38).310Hypertension1.66 (0.47–5.89).430Anemia1.61 (0.21–12.60).649Creatinine, μmol/l0.998 (0.995–1.00).096eGFR, ml/min/1.7321.01 (0.99–1.02).2991 (0.99–1.01).472Proteinuria, g/24 hours1.07 (0.94–1.22).319LDH, U/l1.00 (0.99–1.00).361broken RBC0.42 (0.04–4.62).476ANA0.55 (0.07–4.23).564dsDNA1.53 (0.59–3.98).385C3, g/l0.69 (0.06–8.00).768C4, g/l1.02 (0.02–48.00).991AI score0.99 (0.87–1.12).825Endocapillary hypercellularity1.08 (0.72–1.63).717Neutrophils and/or karyorrhexis0.84 (0.57–1.23).374Fibrinoid necrosis0.96 (0.57–1.62).874Hyaline deposits (wire loop and/or hyaline thrombi)1.16 (0.67–1.99).599Cellular/fibrocellular crescents0.95 (0.73–1.24)0.713Interstitial inflammation1.06 (0.67–1.69)0.797CI score0.86 (0.71–1.04)0.117Total glomerulosclerosis (global + segmental)0.60 (0.39–0.93)0.021.62 (0.40–0.95).027Fibrous crescents0.51 (0.21–1.28)0.154Interstitial fibrosis1.07 (0.71–1.60)0.756Tubular atrophy1.02 (0.65–1.62)0.918 Univariate and multivariable Cox regression analysis for the primary outcome of renal function recovery in the TMA cohort. DISCUSSION In this study, we included 1218 LN patients, assessing the relationship between renal TMA and renal outcomes. Of LN patients, 5.17% had kidney biopsies showing TMA. After PSM, patients with renal TMA exhibited lower scores on the SLEDAI and AI scores in renal biopsies. Multivariate analysis revealed that renal TMA was an independent predictor of poorer kidney recovery outcomes and a higher prevalence of RRT. The proportion of glomerulosclerosis is a predictive factor for renal function recovery in LN patients with renal TMA. Diagnosing renal TMA in LN is challenging and requires experienced pathologists. However, renal TMA is not uncommon in LN patients. Our study found that 5% of LN renal biopsies showed kidney TMA changes. Although LN patients with renal TMA had lower SLEDAI, their kidney recovery was worse. In LN patients, the TMA confirmed by renal biopsy is important in determining the prognosis of the kidneys. In children with LN, renal TMA was an independent risk factor for the development of end-stage renal disease [19, 20]. In LN patients, renal TMA serves as an independent risk factor for kidney survival, and activation of the lectin pathway and alternative pathway contributes to the pathogenesis of TMA [5, 21]. Notably, among patients with renal TMA, 6.3% (4/63) were also diagnosed with systemic TMA, underscoring the importance of renal biopsy findings even in patients without systemic TMA. Our research broadens the utility of renal TMA by enhancing its role in predicting renal outcomes for LN patients. The LN-TMA population we studied represents the largest cohort in recent years, surpassing the previous maximum of 50 cases [9]. In previous studies in China (24 East Asian patients), Brazil (27/43 Caucasian), and India (50 no detailed racial information), renal TMA in patients with LN is associated with adverse clinicopathological presentation and poor outcome [8, 9, 22]. However, this conclusion has been questioned due to the relatively short follow-up periods in those studies. In certain studies, renal TMA has been found not to significantly affect the renal outcomes of LN in Mexico and the USA [10, 11]. The discrepancy may be attributed to the smaller number of cases (Mexico: 23, USA: 13), specific patient selection (Mexico: proliferative LN), potential racial and ethnic differences (Mexico: all Hispanic, USA: 11/13 Black), and relatively shorter follow-up durations [10, 11, 23]. Renal TMA in LN is multifactorial, with potential contributions from the complement system, antiphospholipid syndrome (APS), thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS), and drug-related causes [4]. The role of inherited and acquired complement disorders in SLE and TMA has been highlighted, with mutations in complement factor H, factor I, factor B, thrombomodulin, and MCP/CD46 contributing to the development of TMA [24]. While our study adds to the understanding of the association between TMA and kidney function recovery, the underlying mechanisms remain unclear and require further investigation. Our study identified total glomerulosclerosis as significant risk factors associated with an adverse prognosis in LN patients with renal TMA. In other disease contexts involving renal TMA, glomerulosclerosis has likewise been identified as a significant risk factor for adverse renal outcomes [18, 25]. A higher percentage of glomerulosclerosis is linked to the progression of chronic kidney disease [26]. When glomerulosclerosis is extensive, avoid overtreatment, which can cause infections and complications, and instead consider biopharmaceuticals that specifically target the transition from acute changes to chronic injuries [26]. Even in cases of dialysis patients, a low proportion of glomerular sclerosis means recovery remains possible with treatment. There are several limitations to our study. First, this study was based on a retrospective analysis of a Chinese cohort from a single center, which may limit the generalizability of the findings to other ethnicities and populations. Validation in larger, multicenter, and ethnically diverse cohorts is warranted. Additionally, the retrospective design and long study period may have influenced the results. Although PSM was applied to minimize selection bias, residual confounding or overmatching may still have occurred. Furthermore, the present study was restricted to the assessment of TMA based on renal biopsy specimens, without further distinction between acute and chronic phases, as these represent consecutive pathological processes that may coexist in the same patient. In addition, we did not have comprehensive data on systemic TMA, which limits the generalizability and application of our results. Finally, treatment strategies in this observational study were guided by physicians’ clinical judgments, which may have varied over time, rather than standardized protocols, and the limited sample size prevented a more detailed evaluation of therapeutic effects. Therefore, the impact of different treatment modalities on TMA warrants further investigation. CONCLUSION In conclusion, renal TMA is significantly associated with poorer renal function recovery in LN patients. The degree of glomerulosclerosis in renal biopsy can help doctors assess the likelihood of renal function recovery in LN patients with renal TMA and optimize individualized treatment decisions. Supplementary Material